Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer

MET inhibition is effective in some MET-amplified esophagogastric cancer (EGC) patients, but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired resistance in a patient after a two-year response to M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Kwak, Eunice L., Ahronian, Leanne G., Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Ryan, David P., Lennerz, Jochen K., Iafrate, A. John, Bardelli, Alberto, Hong, Theodore S., Corcoran, Ryan B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670804/
https://ncbi.nlm.nih.gov/pubmed/26432108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0748
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados